Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Acessos
Links relacionados
Similares em
SciELO
Compartilhar
Gen
versão impressa ISSN 0016-3503versão On-line ISSN 2477-975X
Resumo
VILLALOBOS, Danielinne; VALBUENA, Hernán; RALEIGH, Rosalia e CHACIN, José Antonio. Beneficios del reemplazo enzimático con imiglucerasa sobre los hallazgos clínicos y de laboratorio en pacientes pediátricos con enfermedad de gaucher no neuronopática. Gen [online]. 2009, vol.63, n.3, pp.167-169. ISSN 0016-3503.
To evaluate the therapeutic response reached with the administration of the enzymatic replacement with Imiglucerase in patients with non - neuropathic Gaucher disease in the pediatric age of the Dr. Adolfo Pons Hospital. Patients and Methods: This is a prospective descriptive study from January 2007 until March 2008, 5 patients were included in pediatric age understood between 3 and 14 years of both sexes (3 masculine sex and 2 feminine sex) by diagnosis of non - neuropathic Gaucher disease at the Dr Adolfo Pons Hospital, who were treated by enzymatic replacement with imiglucerase. The 5 received in continuous form Imiglucerase to dose of 60 U/kg/weight every 15 days,3 patients for one year and 2 patients for 6 months, appraisement the value of the hemoglobin, white count, and clinical decrease of the visceromegaly which were verify before and after the beginning of the imiglucerase every 3 months up to 6 and 12 months. Results: The average of hemoglobin pre-treatment of the patients was 9, 72 ± 1,42 whereas the average level at the end of the observation was of 11,84 ± 0,39. White count pre- treatment 4150± 2075, 13 post- treatment 7100 ±2488, 97. Platelets pre- Treatment: 90280 ±18135, 37 ultimately 330800 ± 298706, 72. Splenomegaly: pretreatment 75 % of the patients presented mild to moderate splenomegaly at the end of the observation, 75 % didnÊt have visceromegaly and 25 % presented decrease of 30 %. Hepatomegaly: pre- treatment the 80 % present hepatomegaly mild to moderate at the end of the observation 40 % solved the hepatomegaly. Conclusions: The enzymatic replacement with imiglucerase turns out to be effective for the treatment of the non - neuropathic Gaucher disease demonstrated by the improvement of the clinical parameters and of laboratory. Being nowadays the first therapeutic alternative for Gaucher disease treatment.
Palavras-chave : Non - neuropathic Gaucher disease; imiglucerase; children.













